NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis

NCT02648035

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Rheumatoid Arthritis

Interventions: Tocilizumab

Countries: Greece

The purpose of this study is to evaluate the percentage of participants treated with subcutaneous (SC) Tocilizumab who are still on treatment after 52 weeks and the factors that play a major role in continuation of treatment.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

\- Aged \>/= 18 years of age with rheumatoid arthritis (RA) for whom the treating physician has made the decision to start subcutaneous (SC) Tocilizumab (TCZ) treatment according to approved label within 4 weeks prior to enrolment.

Exclusion Criteria:

* Participants who have been receiving Tocilizumab (TCZ) for more than 4 weeks prior to enrolment.
* Participants who have received TCZ in past treatments.
* Participants who have received treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) of starting treatment TCZ SC.
* Participants with a history of autoimmune disease or of any joint inflammatory disease other than rheumatoid arthritis (RA).

Locations (26)

Agrinio, Greece
Athens, Greece
Athens, Greece
Athens, Greece
Áno Patísia, Greece
Chania, Greece
Drama, Greece
Eleusina, Greece
Haidari, Greece
Ioannina, Greece
Kalithea, Athens, Greece
Karditsa, Greece
Kavala, Greece
Kifissia, Greece
Larissa, Greece
Mytilene, Greece
Néa Smýrni, Greece
Pátrai, Greece
Pátrai, Greece
Serres, Greece
Serres, Greece
Thessaloniki, Greece
Thessaloniki, Greece
Thessaloniki, Greece
Véroia, Greece
Volos, Greece